For filings with the FCA include the annex |
|
||||
For filings with issuer exclude the annex |
|
||||
|
|||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
|||||
|
|
||||
1. Identity of the issuer or the underlying issuer |
Oxford Biomedica plc |
||||
2 Reason for the notification (please tick the appropriate box or boxes): |
|||||
An acquisition or disposal of voting rights |
√ |
||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
√ |
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
||||
An event changing the breakdown of voting rights |
|
||||
Other (please specify): |
|
|
|||
3. Full name of person(s) subject to the |
Aviva plc & its subsidiaries |
||||
4. Full name of shareholder(s) |
Registered Holder:
Chase (GA Group) Nominees Limited 202,248,884*
State Street Nominees Limited 5,921,129*
*denotes direct interest
Chase (GA Group) Nominees Limited 17,681,614
Chase Nominees Limited 7,709,254
Vidacos Nominees Limited 12,132,128
|
||||
5. Date of the transaction and date on |
16 March 2017 |
||||
6. Date on which issuer notified: |
17 March 2017 |
||||
7. Threshold(s) that is/are crossed or |
8% to 7% Change at Direct Interest Level (Box 8A) |
||||
8. Notified details: |
|||||||||||
A: Voting rights attached to shares viii, ix |
|||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
|||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
|||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
|||||||
Ordinary Shares
|
293,797,657* |
293,797,657* |
284,531,412 |
247,008,416 |
37,522,996 |
7.998% |
1.215% |
||||
|
|||||||||||
* Includes Right to Recall Loaned Shares (5,791,351)
|
|||||||||||
B: Qualifying Financial Instruments |
|||||||||||
Resulting situation after the triggering transaction |
|||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
|||||||
RIGHT TO RECALL LOANED SHARES |
N/A |
N/A |
8,191,351*
*DIRECT INTEREST
|
0.265% |
|||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||
Resulting situation after the triggering transaction |
||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|
|
|
|
|
|
Nominal |
Delta |
|
|
Total (A+B+C) |
|
Number of voting rights |
Percentage of voting rights |
292,722,763 |
9.478% |
9. Chain of controlled undertakings through which the voting rights and/or the |
||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See Section 4 |
|
11. Number of voting rights proxy holder will cease to hold: |
|
|
12. Date on which proxy holder will cease to hold voting rights: |
|
|
|
||
|
|
|
14. Contact name: |
Tim Watts |
|
15. Contact telephone number: |
01865 783000 |
|